JSM 2012 Online Program
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Online Program HomeActivity Details
|
|||
9 * ! | Sun, 7/29/2012, 2:00 PM - 3:50 PM | HQ-Sapphire EF | |
Journeys to Targeted Therapies and Personalized Medicines: Three Stories — Invited Papers | |||
JSM 2012 Host Local Chapter - San Diego , Biopharmaceutical Section | |||
Organizer(s): Christy Chuang-Stein, Pfizer Inc., Xin Huang, Pfizer Inc., Qiang Casey Xu, FDA | |||
Chair(s): Christy Chuang-Stein, Pfizer Inc. | |||
2:05 PM | Gefitinib from Phase I Responses to a Personalized Medicine — Anna Osmukhina, AstraZeneca ; Andrew Stone, AstraZeneca | ||
2:30 PM | Alimta (Pemetrexed) as a Treatment for Nonsquamous, Nonsmall-Cell Lung Cancer — Patrick M Peterson, Eli Lilly and Company | ||
2:55 PM | Xalkori® The First Prospectively Identified Precision Medicine for Treatment of Non-Small Cell Lung Cancer (NSCLC): Development Opportunities and Challenges — Paulina Selaru, Pfizer Inc. ; Yiyun Tang, Pfizer Inc. ; Bo Huang, Pfizer Inc. | ||
3:20 PM | Discussant: Rajeshwari Sridhara, FDA | ||
3:40 PM | Floor Discussion |
2012 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.